Publications 2007

Can't find the PDF you are looking for? Email Jessica Kohn for assistance.


Publications: 2007

1 - Herlyn, M., Halaban, R., Ronai, Z., Schuchter, L., Berwick, M., and Pinkel, D. Roadmap for new opportunities in melanoma research. Semin. Oncol. 34: 566-576, 2007.   (PDF)

2 - Fukunaga-Kalabis, M., Martinez, G., Telson, S.M., Liu, Z.-J., Balint, K., Juhasz, I., Elder, D.E., Perbal, B., Herlyn, M.: Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 27(18): 2552-2560, 2007.  PDF

3 - Smalley, K.S.M. and Herlyn, M.: Is knowledge about the genetic and epigenetic alterations in melanoma a basis for targeted therapy? Exp.Dermatol, 844-845, 2007.  PDF

4 - Smalley, K.S.M., Herlyn, M., Flaherty, K.T. Targeting BRAF/MEK inhibitors in melanoma therapy: New hope or another false dawn? Exp. Rev. Derm. 2(2): 179-190, 2007  PDF

5 - Smalley, K.S. and Herlyn, M.: In Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Eds., The Online metabolic and molecular bases of inherited disease. Enzyclopedia of Cancer, Springer, Heidelberg, Chapter 44: Malignant melanoma, pp 1-27, 2007.  PDF

6 - Zabierowski, S. and Herlyn, M.: Role of stem cells in melanoma progression: Hopes for a better treatment. Expert Rev. Dermatol. 2: 191-201, 2007. PDF

7 - Lee, J.T., and Herlyn, M.: Old disease, new culprit: tumor stem cells in cancer. J. Cell. Physiol. 213: 603-609, Sept. 4 (Epub ahead of print), 2007. PDF

8 - Gaddipati, H., and Herlyn, M.: Association of polymorphisms of FAS-1377, FAS-670, and FASL-844 genes with risk factors for cutaneous malignant melanoma. Cancer J. 13: 226-228, 2007.

9 - Spittle, C., Ward, M.R., Nathanson, K.L., Gimotty, P.A., Rappaport, E., Brose, M.S.., Medina, A., Letrero, R., Herlyn, M., Edwards, R.H.: Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma. J. Molec. Diagn. 9: 464-471, 2007. PDF

10 - Wenke, A.K., Kjellman, C., Lundgren-Akerlund, E., Uhlmann, C., Haass, N.K., Herlyn, M., Bosserhoff, A.K.: Expression of integrin alpha 10 is induced in melanoma. Cell Oncolo. 29: 373-386, 2007. PDF

11 - Okawa, T., Michaylira, C. Z., Kalabis, J., Stairs, D. B., Nakagawa, H., Andl, C., Johnstone, C. N., Klein-Szanto, A. I., El-Deiry, W. S., Cukierman, E., Herlyn, M., Rustgi, A. K.: The functional interplay between EGFR, hTERT activation and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induce tumor development, invasion and differentiation. Genes and Development, 21(21) 2788-2803, 2007. PDF

12 - Fukunaga-Kalabis, M., Herlyn, M.: Unraveling mysteries of the multifunctional protein SPARC. J Invest. Dermatol., 127(12): 2497-2498, 2007. PDF

13 - Herlyn, M. Farming cells to rebuild skin and melanoma. Cancer Biol Ther. 2007 Mar;6(3):467-71.   PDF

14 - Kazianis, S. and Herlyn, M.: In Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Eds., The Online metabolic and molecular bases of inherited disease. Enzyclopedia of Cancer, Springer, Heidelberg,   Chapter 44: Malignant melanoma, pp 1-27, 2007.

15 - Fukunaga-Kalabis, M., Li, L., Herlyn, M.: three-dimensional culture of human skin. AACR Educational Book, pp 203-206, 2007 AACR Annual Meeting, April 14-18, 2007.

16 - Thomas, R.K., Baker, A.C., Debiasi, R.M., Winckler, W., Laframboise,  T., Lin, W.M., Wang, M., Feng, W., Zander, T., Macconnaill, L.E.,  Lee, J.C., Nicoletti, R., Hatton, C., Goyette. M., Girard, L.,  Majmudar, K., Ziaugra, L., Wong, K.K., Gabriel, S., Beroukhim, R.,  Peyton, M., Barretina, J., Dutt, A., Emery, C., Greulich, H., Shah,  K., Sasaki, H., Gazdar, A., Minna, J., Armstrong, S.A., Mellinghoff,  I.K., Hodi, F.S., Dranoff, G., Mischel, P.S., Cloughesy, T.F.,  Nelson, S.F., Liau, L.M., Mertz, K., Rubin, M.A., Moch, H., Loda, M.,  Catalona, W., Fletcher, J., Signoretti, S., Kaye, F., Anderson, K.C.,  Demetri, G.D., Dummer, R., Wagner, S., Herlyn, M., Sellers, W.R.,  Meyerson, M., Garraway, L.,A.: High-throughput oncogene mutation  profiling in human cancer. Nat Genet. 39(3): 347-351, 2007.  PDF

17 - Seidl, H., Richtig, E., Tilz, H., Stefan, M., Schmidbauer, U., Asslaber, M., Zatloukal, K., Herlyn, M., Schaider, H.: Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma. Hum Pathol. 38(5): 768-780, 2007.   PDF

18 - Lopez-Bergami, P., Huang, C., Bar-Eli, M., Herlyn, M., Mahale, A., Aaronson, S., Ronai, Z.: Re-wired ERK-JNK signaling pathways in melanoma. Cancer Cell. 11(5): 447-460, 2007.

19 - Lioni, M., Brafford, P., Andl, A., Rustgi, A., El-Deiry, W., Herlyn, M., Smalley, K.S.M.: Dysregulation of Claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. Am. J. Pathol., 170(2): 709-722, 2006.    PDF

20 - Smalley, K.S.M., Contractor, R., Haass, N.K., Kulp, A. N., Atilla-Gokcumen, G.E., Williams, D.S., Bregman, H., Flaherty, K.T., Soengas, M.S., Meggers, E., Herlyn, M.: An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res. 67: 209-217, 2007.   PDF

21 - Smalley, K.S., Contractor, R., Haass, N.K., Lee, J.T., Nathanson, K.L., Medina, C.A., Flaherty, K.T., Herlyn, M.: Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Brit. J. Cancer. 96(3): 445-449.    PDF

22 - Kumar, S.M., Yu, H., Edwards, R., Chen, L., Kazianis, S., Brafford, P., Acs, G., Herlyn, M., Xu, X.: Mutant V600E BRAF increases hypoxia inducible factor-1a expression in melanoma. Cancer Res. 67(7): 3177-3184, 2007.   PDF

23 - Meier, F., Busch, S., Lasithiotakis, K., Kulms, D., Garbe, C., Maczey, E., Herlyn, M., and Schitteck, B.: Combining targeting MAPK and AKT signaling pathways is a promising strategy for melanoma therapy. Br J Derm. 156(6): 1204-1213, 2007. PMID 17388918

24 - Pinnix, C.C., and Herlyn, M.: The many faces of Notch signaling in skin-derived cells. Pigment Cell Mel Res., 20(6): 458-465, 2007   PDF

25 - Kumar, K.G.S., Liu, J., Yu, D., Thomas-Tikohenko, A., Herlyn, M., Fuchs, S.Y.: Raf inhibitor stabilizes receptor for type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol. Ther., 6(9): 1437-1441, 2007.  PDF